Can EF Decrease After TAVR?
Yes, left ventricular ejection fraction can decrease slightly after TAVR in approximately 21% of patients, but this decline is not associated with worse clinical outcomes or survival.
Magnitude and Frequency of EF Changes
The pattern of LVEF changes after TAVR follows a predictable distribution 1:
- Approximately 21% of patients experience a clinically significant decrease in LVEF (≥5% decline) 1
- About 57% maintain stable LVEF (within ±5% of baseline) 1
- Roughly 22% show improvement in LVEF (≥5% increase) 1
The mean decrease in the worsened group is approximately 10.8% ± 3.9% from baseline 1.
Clinical Significance and Outcomes
Despite measurable decreases in LVEF, patients with post-TAVR EF decline do not experience worse survival, increased rehospitalization rates, or worse functional status compared to those with stable or improved EF 1. This finding is reassuring and suggests that modest LVEF reductions after TAVR represent a benign phenomenon in most cases.
However, more recent large-scale registry data provides important nuance 2:
- Patients who develop new left bundle branch block (LBBB) after TAVR experience a mean 2.8% lower LVEF at one year compared to those without LBBB 2
- New LBBB occurs in approximately 16% of TAVR patients and is associated with increased mortality (adjusted HR 1.19), rehospitalization (adjusted HR 1.23), and pacemaker requirement 2
Predictors of EF Changes
Factors Associated with EF Improvement 3:
- Baseline LVEF <40% shows the greatest improvement potential (from 33% to 43% at 12 months) 3
- Lower baseline LVEF is the strongest independent predictor of reverse remodeling 3
Factors Associated with Lack of EF Improvement 3:
- Coronary artery disease (OR 1.80) 3
- Prior myocardial infarction (OR 2.07) 3
- Permanent pacemaker implantation (OR 1.93) 3
Mechanism Considerations
The transapical approach does not appear to significantly influence EF changes, as progressive reduction in sheath diameter (to 18F) showed no significant effect on LVEF trajectory 1. This suggests that the access site trauma is not the primary driver of post-TAVR EF changes.
Clinical Monitoring Implications
Based on ACC/AHA expert consensus 4:
- Baseline echocardiography before discharge establishes new reference values for valve function and LVEF 4
- Follow-up at 6 months and annually is recommended for stable patients 4
- More frequent monitoring is warranted if complications develop, particularly new conduction abnormalities 4
Key Caveats
While modest EF decreases are generally benign, clinicians should remain vigilant for:
- New LBBB development, which portends worse outcomes including lower LVEF, higher mortality, and increased pacemaker requirements 2
- Concurrent cardiac conditions including coronary disease, which may limit recovery potential 3
- The distinction between expected post-procedural changes versus true valve dysfunction or other complications requiring intervention 4